Ascletis Pharma Inc. (OTCMKTS:ASCLF) Short Interest Up 576.6% in December

Ascletis Pharma Inc. (OTCMKTS:ASCLF) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 185,545 shares, an increase of 576.6% from the December 15th total of 27,422 shares. Based on an average daily trading volume, of 1,836 shares, the short-interest ratio is currently 101.1 days. Based on an average daily trading volume, of 1,836 shares, the short-interest ratio is currently 101.1 days.

Ascletis Pharma Trading Down 1.3%

ASCLF traded down $0.02 on Monday, hitting $1.53. 13,000 shares of the company were exchanged, compared to its average volume of 8,500. The business’s fifty day moving average is $1.63 and its 200 day moving average is $1.50. Ascletis Pharma has a fifty-two week low of $0.62 and a fifty-two week high of $2.29.

Ascletis Pharma Company Profile

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).